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Abstract
Background: Amyotrophic lateral sclerosis (ALS) is a disease affecting the central nervous system that is either
sporadic or familial origin and causing the death of motor neurons. One of the genetic factors contributing to the
etiology of ALS is mutant SOD1 (mtSOD1), which induces vulnerability of motor neurons through protein
misfolding, mitochondrial dysfunction, oxidative damage, cytoskeletal abnormalities, defective axonal transport,
glutamate excitotoxicity, inadequate growth factor signaling, and neuroinflammation. Bee venom has been used in
the practice of Oriental medicine and evidence from the literature indicates that BV plays an anti-inflammatory or
anti-nociceptive role against inflammatory reactions associated with arthritis and other inflammatory diseases. The
purpose of the present study was to determine whether bee venom suppresses motor neuron loss and microglial
cell activation in hSOD1
G93A mutant mice.
Methods: Bee venom (BV) was bilaterally injected (subcutaneously) into a 14-week-old (98 day old) male
hSOD1
G93A animal model at the Zusanli (ST36) acupoint, which is known to mediate an anti-inflammatory effect.
For measurement of motor activity, rotarod test was performed and survival statistics were analyzed by Kaplan-
Meier survival curves. The effects of BV treatment on anti-neuroinflammation of hSOD1
G93A mice were assessed via
immunoreactions using Iba 1 as a microglia marker and TNF-a antibody. Activation of ERK, Akt, p38 MAP Kinase
(MAPK), and caspase 3 proteins was evaluated by western blotting.
Results: BV-treated mutant hSOD1 transgenic mice showed a decrease in the expression levels of microglia marker
and phospho-p38 MAPK in the spinal cord and brainstem. Interestingly, treatment of BV in symptomatic ALS
animals improved motor activity and the median survival of the BV-treated group (139 ± 3.5 days) was 18% greater
than control group (117 ± 3.1 days). Furthermore, we found that BV suppressed caspase-3 activity and blocked the
defects of mitochondrial structure and cristae morphology in the lumbar spinal cord of hSOD1
G93A mice at the
symptomatic stage.
Conclusion: From these findings, our research suggests BV could be a potential therapeutic agent for anti-
neuroinflammatory effects in an animal model of ALS.
Background
Amyotrophic lateral sclerosis (ALS) is a severe paralytic
disorder of the central nervous system (CNS) that is
characterized by age-related degeneration or elimination
o fu p p e ra n dl o w e rl a r g em o t o rn e u r o n so ft h em o t o r
cortex, brainstem, and spinal cord [1]. ALS symptoms
are characterized by muscle weakness, atrophy, spasti-
city, and paralysis [2]. Riluzole therapy has been shown
to only improve the survival of ALS patients by a few
months and has several side-effects, including asthenia,
nausea, anorexia, and diarrhea [3]. Therefore, a safer
and more effective therapy for ALS patients is needed in
order to reduce the pain associated with this disease.
Most ALS patients have the sporadic form of the disease
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any medium, provided the original work is properly cited.while 5-10% of ALS cases are of the familial type. Famil-
ial ALS (fALS) cases are caused by autosomal dominant
mutations of the human Cu-Zn superoxide dismutase 1
(hSOD1) gene [4]. An animal model of ALS has been
characterized in mice that carry the mutated hSOD1
gene with a glycine to alanine substitution at the 93
rd
codon (SOD1
G93A). These animals display progressive
motor neuron degeneration that is similar to that
observed in cases of human ALS [5]. In vivo and in vitro
studies using mutant hSOD1 transgenic mice have
demonstrated multiple cellular pathogenic events in
motor neurons such as glutamate excitotoxicity, mito-
chondrial dysfunction, protein misfolding, neurofilament
accumulation, and oxidative stress [2,6,7].
Neuroinflammation is a pathological feature present in
ALS patients and in the mutant hSOD1 mouse model [8].
As critical mediators of inflammation, activated microglia
and elevated levels of tumor necrosis factor-alpha
(TNF-a) are detected in the CNS of ALS patients and in
hSOD1
G93A transgenic mice [9]. Previous findings point
towards the critical involvement of microglia in the devel-
opment of motor neuron disease; however the nature of
microglial-neuronal interactions that lead to motor neuron
degeneration remains unknown. One possibility that has
been extensively studied in the context of other neurode-
generative diseases, especially Alzheimer’s disease (AD), is
the notion that chronic and detrimental microglial neu-
roinflammation contributes to neuronal degeneration [10].
Another study demonstrated that p38, a 38 kDa Stress
Activated Protein Kinase/Mitogen-Activated Protein
Kinase (SAPK/MAPK), has a key role in the development
of inflammation [11]. Inhibition of p38 has been shown to
produce anti-inflammatory effects by reducing cytokines
such as TNF-a, interleukin-1 (IL-1), and nitric oxide
synthetase (NOS) as well as by decreasing Cox-2 in
inflammatory cells [11]. Elevated levels of TNF-a and
TNF-a medicated signaling pathways are evident in a
large number of neurological disorders including multiple
sclerosis (MS), AD, Parkinson’sd i s e a s e( P D ) ,a n dA L S
[12-15]. Furthermore, pro-inflammatory cytokines, such as
TNF-a and interferon-gamma (IFN-g) have been proposed
to be involved in ALS-like microglial activation and
inflammation-induced motor neuron death [16,17].
Bee venom (BV), which is also known as apitoxin, is
extracted from honeybees and is commonly used in
Oriental medicine. The anti-inflammatory action of BV
has shown to reduce pain in patients with chronic rheu-
matoid arthritis and osteroarthritis [18]. However, the
mechanism by which these anti-inflammatory properties
relieve the neuroinflammation associated with neurode-
generative disease is not clear. In order to explore this
therapeutic mechanism, we investigated the anti-inflam-
matory effects of BV on motor function and survival in
SOD1
G93A mutant mice.
The present study showed decreased levels of TNF-a
and the deactivation of p38 MAPK downstream of the
TNF-a signaling pathway in both the brainstem and spinal
cord of hSOD1
G93A mice after treatment with BV in the
hind limbs at the ST36 acupoint. Interestingly, BV treat-
ment reduced the number of microglial cells and astro-
cytes, and dramatically increased the expression of MAP2
in motor-related regions of the brainstem and spinal cord
in comparison with age-matched hSOD1
G93A control
mice. Additionally, we showed that BV suppressed cas-
pase-3 activity and reduced the disruption of mitochon-
drial structure and cristae morphology in the lumbar
spinal cord of hSOD1
G93A mice. Furthermore, BV treat-
ment improved the motor coordination and prolonged the
life span of familial mutant ALS animals at a symptomatic
stage. Based on these findings, we suggest that BV has a
neuroprotective effect against motor neuron cell death
and suppresses neuroinflammation-induced disease pro-
gression in symptomatic ALS mice model.
Methods
Animals
All mice were handled in accordance with the guidelines
of the United States National Institutes of Health
(Bethesda, MD). The protocols were approved by the
Institutional Animal Care and Use Committees of the
Korea Institute of Oriental Medicine. Hemizygous trans-
genic B6SJL mice carrying a glycine to alanine base pair
mutation at the 93
rd codon of the cytosolic Cu/Zn
superoxide dismutase gene (hSOD1
G93A) were originally
obtained from the Jackson Laboratory (Bar Harbor,
ME). Transgenic mice were identified by PCR as
described previously [4]. The hSOD
G93A mice developed
the initial signs of neuromuscular deficits, such as leg
tremors and loss of the hindpaw extension reflex, at
approximately 15 weeks of age. At 16 weeks, they
showed marked locomotor impairment with paralysis
and muscular atrophy of the hind limbs. These animals
died due to respiratory failure at 18-20 weeks of age.
The 14-week-old transgenic mice were considered to be
symptomatic; mice of this age were used for the study.
All mice were kept in standard housing with free access
to water and standard rodent chow.
Bee venom treatment
Bee venom was purchased from Sigma (St. Louis, MO)
and diluted with saline. At a dose of 0.1 μg/g, bee
venom was bilaterally injected (subcutaneously) into 14-
week-old (98 day old) male hSOD1
G93A transgenic mice
(hSOD1
G93A-BV, n = 11) at the Zusanli (ST36) acu-
point, which is known to mediate an anti-inflammatory
effects [19]. BV treatment was performed two times a
week at a dose of 0.1 μg/g. According to the human
acupoint landmark and a mouse anatomical reference
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below and lateral to the anterior tubercle of the tibia.
Control animals were bilaterally injected (subcuta-
neously) with an equal volume of saline at the ST36
acupoint (hSOD1
G93A, n = 11).
Behavioral analysis (rotarod test)
Mice were trained for 1 week in order for them to accli-
mate to the apparatus. After training of the hSOD1
G93A
mice, their basal motor activity was measured with a
rotarod apparatus (Ugo, Basil, Italy). Motor coordination
was assessed by measuring the length of time that the
mice remained on the rotating rod (10 rpm) as was pre-
viously described [21].
Each animal underwent three trials and the average
time spent on the rod was determined for each group.
Rotarod testing was conducted at the same time to
reduce environmental variables such as light cycle and
temperature.
Life span study
For lifespan analysis, SOD1
G93A mice were assessed for a
total of 100 days and divided into the following treatment
groups: saline-treated SOD1
G93A mice (n = 11) and
SOD1
G93A mice treated with BV at 14 weeks (98 day old)
old (n = 11). We defined “death” that is, the end point of
life for hSOD1
G93A mice as the first day on which the
mouse stopped movement on either side, after which
time the mouse was no longer able to eat due to severe
hindlimb paralysis. Mice were then sacrificed to reduce
further pain from respiratory failure according to animal
care guidelines. The life span analysis was carried out in
male SOD1
G93A mice. Survival statistics were analyzed by
Kaplan-Meier survival curves by Prism 4.0 software
(GraphPad Software, San Diego, CA) and Sigmaplot
10 software (Systat Software, Inc. Richmond, CA).
Values were analyzed by a one-way ANOVA followed
by a Dunn’s multiple-comparison test. All statistics were
performed and graphs were developed using Prism 4.0.
Tissue processing and immunohistochemistry
At 18 days after treatment with BV or saline, hSOD1
G93A
mice were deeply anesthetized with pentobarbital. They
were transcardially perfused with phosphate-buffered sal-
ine (PBS), followed by a perfusion with a fixative solution
containing 4% paraformaldehyde in PBS. The spinal cord
and brain were dissected out and fixed overnight in 4%
paraformaldehyde at 4°C, transferred to 30% sucrose, and
then frozen. The spinal cord and brainstem were
embedded in OCT compound and serially cut on a cryo-
stat into 40-μm thick coronal sections. The sections were
then floated in PBS and quenched with 30% methanol
and hydrogen peroxide to eliminate endogenous peroxi-
dase activity. After blocking in 5% normal goat serum at
room temperature, sections were incubated with the pri-
mary antibodies, which included Iba-1 (Wako, Osaka,
Japan) at 1:5000 or TNF-a (Cell Signal, Beverly, MA) at
1:100. All tissue sections were rinsed in PBST (PBS with
0.3% Tween 20) and incubated in secondary antibody
(1:1000) for 1 h. Following incubation, all sections were
rinsed and stained using Vectastain ABC kits (Vector,
Burlingame, CA) according to the manufacturer’s
instructions. For visualization, 3, 3’-diaminobenzidine
(DAB)-H2O2 substrate was used with a hematoxylin
counterstain. After rinsing, all samples were dehydrated
in increasing concentrations of ethanol, cleared in xylene,
and coverslipped using Permount mounting medium
(Fisher Scientific, Pittsburgh, PA). Immunostained tissues
were observed with a light microscope (Olympus, Tokyo,
Japan). Every fifth spinal cord or brainstem section
(50 μm) from saline- (n = 3) or BV-treated hSOD1
G93A
mice (n = 4) was stained with Iba 1 or TNF-a antibody.
Cell counting for immunoreactive cells was performed
using an image analysis software (IMT i-solution, Hack-
ettstown, NJ).
Western blot
At 14 days after treatment with BV or saline, brains and
spinal cords were dissected and homogenized in RIPA
buffer (50 mM Tris-Cl pH 7.4, 1% NP-40, 0.1% SDS, and
150 mM NaCl). Homogenized tissues were centrifuged at
14,000 rpm for 20 min at 4°C. Proteins were quantified
using the BCA assay kit (Pierce, Rockford, IL). Samples
were electrophoresed through SDS-polyacrylamide gels
and transferred to nitrocellulose membranes. Blots were
blocked with 5% non-fat milk in TBS for 1 h prior to
incubation with antibodies. Various primary antibodies
were utilized in this study, including anti-SOD1 (Calbio-
chem, La Jolla, CA), anti-tubulin (Abcam, Cambridge,
UK), anti-Akt (Cell Signaling, Beverly, MA), anti-pAkt
(Cell Signaling), anti-p38 (Cell Signaling), anti-phospho-
p38 (Cell Signaling), anti-Iba 1 (Wako, Osaka, Japan),
and anti-active caspase-3 (Calbiochem). Blots were
probed with HRP-conjugated antibodies (SantaCruz,
Santa Cruz, CA) and developed with enhanced chemilu-
minescence (ECL) reagents (Amersham Pharmacia,
Piscataway, NJ).
Transmission Electron Microscopy (TEM)
BV-treated hSOD1
G93A mice and age-matched controls
were sacrificed and perfused with 2% glutaraldehyde.
The procedure of sample preparation for TEM was
performed as previously described [22].
Statistical analysis
Results are expressed as means ± SEM values. Statistical
evaluations were conducted using the Mann-Whitney
U test for comparisons between BV-treated and
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G93A mice. A t-test was
used to compare the immunoblotting and immunohisto-
chemical data between the BV-treated mice and the
age-matched untreated hSOD1G93A mice. P values less
than 0.05 were considered significant. All analyses were
performed with SPSS 12.0 software (SPSS, Chicago, IL).
Results
The BV treatment increases survival rate and motor
activity in symptomatic hSOD1
G93A transgenic mice
To determine the effects of BV on the survival and
motor activity of hSOD1
G93A mice, BV (0.1 μg/g) was
bilaterally administered (subcutaneously) at ST36 (Fig-
ure 1). As shown in Figure 2, the BV-treated
hSOD1
G93A group displayed a 1.3-fold increase in motor
function at 7 days after treatment with BV as deter-
mined by the rotarod behavioral test compared to age-
matched control mice. Furthermore, we observed that
BV-treated mice had a delay in disease onset and paraly-
sis compared to saline-treated hSOD1
G93A mice. Next,
we examined the survival rate to determine whether BV
treatment prolonged the life span of hSOD1
G93A mice.
The expected life span was assessed by Kaplan-Meier
survival analysis. The median survival of the BV-treated
group (139 ± 3.5 days) was 18% greater than control
group (117 ± 3.1 days). The Kaplan-Meier probability of
survival analysis showed that the BV-treated group had
a significantly improved survival rate (160 ± 3.5 days)
compared to the control group (143 ± 3.1 days) (Figure
3). However, there was no significant difference in body
weight before and after BV treatment (data not shown).
These results indicate that BV acted therapeutically
against the onset of motor dysfunction as well as against
disease progression in hSOD1
G93A mice.
BV reduces microglial cell activation and
neuroinflammation
Microglia activation can be observed in virtually all CNS
pathologies including ALS. However, the role of the
microglial response in many CNS disorders remains
ambiguous, given that these cells exhibit both neuropro-
tective and neurotoxic effects [23]. To demonstrate
whether BV affected neuroinflammation in a familial
ALS animal model, we studied the relationship between
microglia activation and inflammatory factors in sympto-
matic hSOD1
G93A mice. For this experiment, BV or sal-
ine was injected at ST36 in 14-week-old hSOD1
G93A
mice. The effect of BV on activated microglial cells moni-
tored using the Iba-1 antibody in both the brainstem and
lumbar spinal cord of symptomatic hSOD1
G93A mice. As
shown in Figure 4A, the expression level of Iba-1 was
dramatically reduced in both the brainstem and spinal
cord of BV-treated mice in comparison with the control
group. Next, we immunostained lumbar spinal cord sec-
tions from BV- or saline-treated mice (Figure 4B-G). At a
low magnification, Iba-1 immunoreactivity was detected
in both the white and gray matter of the spinal cord in
hSOD1
G93A transgenic mice (Figure 4B,C). At a higher
magnification, Iba-1 immunoreactivity in the ventral
horn of BV-treated hSOD1
G93A mice was significantly
reduced (~2.8 times) as compared to the identical area in
control mice (Figure 4F). In the brainstem of mutant
SOD1 mice, Iba-1 immunoreactive cells were detected as
well (Figure 4D,E). BV caused an approximate 2.4 fold
decrease in microglial activity within the facial nucleus of
the brainstem (Figure 4G).
In order to determine whether BV suppressed neu-
roinflammation by inhibiting of the release of the pro-
inflammatory cytokine TNF-a, we further examined the
Figure 1 Diagram of the experiment schedule. At the beginning of the experiment, the animals were randomly divided into two groups: the
saline-treated group (control) and the BV-treated group. Saline- or BV- (0.1 μg/g) was administrated bilaterally and subcutaneously at ST36 to 98-
day-old hSOD1
G93A male mice (first treatment for saline or BV). Two days after the first saline or BV treatment, saline or BV (0.1 μg/g) was
injected by the same method. A rotarod test for the measurement of motor activity was performed from day 91 to day 114. For the survival test,
saline- and BV-treated mice were observed until they reached 160 days old. Mice used for the biochemical study were sacrificed 18 days after
the first saline- or BV treatment. IHC: immunohistochemistry, WB: western blotting
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saline-treated familial ALS mice. As expected, TNF-a
immunoreactivity in hSOD1
G93A mice was largely con-
fined to the facial nucleus of the brain stem and motor
neurons in the anterior horn of the spinal cord (Figure
5A,C, and 5E). Interestingly, BV caused a significant 4-
fold reduction in TNF-a immunoreactivity in both the
brainstem and lumbar spinal cord (Figure 5B,D, and 5F-
H). These results suggest that BV treatment may be
involved in an anti-neuroinflammatory responses that
reduces motor neuron degeneration and prolongs the
life span of hSOD1
G93A transgenic mice at the sympto-
matic stage.
BV inhibits cell death and disruption of mitochondrial
structure in hSOD1
G93A mice
The caspase family plays an important role in the patho-
genesis of CNS disorders [24]. Caspase-3 activation,
which has been detected in ALS patients [25], and
mutant SOD1 expression have been shown to induce
caspase-dependent neuronal apoptosis in vitro [26]. To
assess whether BV affected mitochondrial cell death in
symptomatic mutant SOD1 mice, we performed immu-
noblotting analysis of homogenates of the spinal cord
and brainstem using a caspase-3 antibody. Expression
levels of the active caspase-3 fragment were markedly
increased in the lumbar spinal cord of hSOD1
G93A mice,
but caspase-3 expression was maintained at a very low
level in the spinal cord of BV-treated hSOD1
G93A mice.
More specifically, caspase-3 expression was found to be
reduced by 80% relative to the level observed in
untreated hSOD1
G93A mice (Figure 6A).
Next, we asked whether BV affected the mitochondrial
ultrastructure in the lumbar spinal cord of symptomatic
hSOD1
G93A mice. We used transmission electron micro-
scopy (TEM) to visualize mitochondria from the anterior
horn of the lumbar spinal cord from BV- or saline-treated
mutant SOD1
G93A mice. In symptomatic familial
hSOD1
G93A mice, mitochondria displayed vacuolation and
broken cristae (Figure 6B,D). By contrast, mitochondrial
cristae were shaped as compact tubules in an orderly fash-
ion in the ventral horn of the spinal cord from BV-treated
(Figure 6C,E). These studies demonstrated that BV serves
a protective role in regulating mitochondrial structure and
cristae morphology.
Next, we asked whether BV-induced signal transduc-
tion pathways affected neuron death and gliosis in
hSOD1
G93A mice. As shown in Figure 7A, Western bolt
analysis revealed an increase in the expression of the
neuronal cell marker MAP2 in both the brainstem and
lumbar spinal cord of BV-treated symptomatic
hSOD1
G93A mice. In addition, GFAP was significantly
reduced in the BV-treated brainstem and spinal cord
when compared with age-matched familial mutant
SOD1 mice (Figure 7B). These data suggest that BV-
treatment at ST36 had a neuroprotective effect via acti-
vation of a cell survival signal transduction pathway,
Figure 2 Effects of BV on rotarod performance of hSOD1
G93A
mice. BV delays the onset of motor impairment in hSOD1
G93A
transgenic mice. B6 G93A-SOD1 mice (n = 11/group) were injected
with saline (squares) or BV at ST36 (circles). Values represent the
mean ± SEM. Significantly improved motor performance was
evident at most time points between 7-9 days after BV treatment as
compared with controls. The Mann-Whitney U test was used to
compare saline-treatment versus BV-treatment in hSOD1
G93A
transgenic mice (**p < 0.005, *p < 0.05). S: second, Con: saline
treated-mice, BV: bee venom treated-mice.
Figure 3 BV prolongs the survival of hSOD1
G93A transgenic
mice. A Kaplan-Meyer analysis illustrates the significant benefits
from BV (0.1 μg/g/98day) compared with the control regarding
survival rate. Mice were bilaterally injected with saline (open circles)
or BV (closed circles) at ST36 (subcutaneously). The mean, median,
minimum, and maximum age of death in saline-treated hSOD1
G93A
mice are 120, 117, 107, 143 day, respectively. The mean, median,
minimum, and maximum age of death in BV-treated hSOD1
G93A
mice are 139, 139, 118, and 160 day, respectively. Con: saline-treated
mice, BV: bee venom-treated mice.
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from gliosis and neuroinflammation.
The effect of BV on cell survival signal transduction
pathways
To evaluate the mechanism by which BV mediates this
neuroprotective activity, we examined the expression
levels of phospho-p38 MAPK and several anti-apoptotic
markers, such as phospho-Akt and phospho-ERK, in
symptomatic hSOD1
G93A mice. Western blotting experi-
ments using anti-phospho-p38 or Ser435-phospho-specific
Akt1 antibodies demonstrated activation of Akt-1 and
deactivation of phospho-p38 in the spinal cord and brain-
stem following treatment with BV (Figure 7D,E). Further-
more, BV-treatment dramatically increased the expression
of phospho-ERK in the spinal cord and brainstem of famil-
ial mutant SOD1 mice (Figure 7F). These biochemical
results support that previous observations indicating that
BV at ST36 improved motor activity and increased survi-
val rates of hSOD1
G93A mice (Figures 2 and 3).
Discussion
The molecular targets and signaling pathways influencing
paralysis in ALS are not completely understood. To date,
several pathogenic mechanisms have been identified that
contribute to atrophy and paralysis in ALS patients,
including protein misfolding, mitochondrial dysfunction,
oxidative damage, cytoskeletal abnormalities, defective
axonal transport, glutamate excitotoxicity, inadequate
growth factor signaling, and neuroinflammation.
In this study, we demonstrated that administration of
BV at a symptomatic stage of disease progression resulted
in increased motor activity and a prolonged life span in
comparison with age-matched control mice. Furthermore,
we observed that BV prevented neuroinflammation-
induced death of motor neurons and alleviated mitochon-
drial disruption in symptomatic SOD1
G93A transgenic
mice.
Microglia in the CNS are immunologically active and
capable of responding to events associated with forma-
tion of the neuronal-glial environment. Moreover, evi-
dence indicating that microglial cells are involved in the
progression of ALS pathogenesis has emerged from sev-
eral lines of investigation. For example, activated micro-
glia are typically found in ALS patients and in mouse
models of ALS [27]. In addition, microglia have been
shown to increase pro-inflammatory cytokines, reactive
oxygen species (ROS), and glutamate in response to sti-
muli from neurons and astrocytes, which include pro-
inflammatory cytokines and neurotrophic factors [28].
The pro-inflammatory cytokine TNF-a is a member of
the TNF superfamily, which is a class of cytokines
known to promote inflammatory signaling [29]. TNF
signaling occurs through many factors including
intracellular signaling pathways, nuclear factor kappa-B
(NF-kB), p38, and c-Jun N-terminal kinase (JNK), which
results in a number of responses such as inflammation,
proliferation, cell migration, and necrosis [30,31]. TNF
signaling has been shown to have several important
functions within the CNS [32], including injury-
mediated microglial and astrocyte activation [33].
Elevated levels of TNF-a and activation of TNF-a-
mediated signaling pathways are evident in a large num-
ber of neurological disorders including AD, PD, and
ALS [13-15]. In addition, cytokines TNF-a has been
proposed to be involved in ALS-like microglial activa-
tion [16], and inflammation by this cytokine has been
shown to induce motor neuron death [17]. In accor-
dance with previous reports [27,15], the present study
showed that microglial cell activation and increased
TNF-a cytokine levels were involved in ALS pathologies
involving both the spinal cord and the facial nucleus of
the brainstem in symptomatic familial hSOD1
G93A mice
(Figures 4, 5). Interestingly, we found that BV adminis-
tration at the ST36 acupoint significantly attenuated
neuroinflammatory events triggered by TNF-a and
microglial cell activation in motor function related-
structures within the spinal cord and brainstem (Figures
4 A ,5 G - H ) .S o m er e p o r t sh a v ea l s os u g g e s t e dt h a tB V
may be an efficient treatment for multiple sclerosis
(MS) and other autoimmune diseases based on the inhi-
bition of TNF-a production [34,35,18]. These findings
suggest that BV treatment may be useful for combating
inflammation in ALS patients.
Previous reports have indicated that a common
mechanism of toxicity associated with the mutant form
of SOD1 is the sequential activation of caspase-1 and cas-
pase-3 [36]. Since caspase-3 activation leads to microglial
cell activation and mitochondrial dysfunction, we exam-
ined whether caspase-3 inactivation was involved in the
anti-inflammatory effect of BV. We found that the levels
of active caspase-3 were significantly reduced in the lum-
bar spinal cord of hSOD1
G93A mice following BV treat-
ment (Figure 6A). Furthermore, the administration of BV
prevented the disruption of mitochondrial cristae and
v a c u o l i z a t i o ni nt h ev e n t r a lh o r no fh S O D 1
G93A mice at
the symptomatic stage (Figure 6B-E). This result suggests
that BV treatment had an anti-inflammatory effect on the
CNS of familial mutant SOD1 mice. Thus, we hypothe-
sized that BV-treatment reduced motor neuron death
and mitochondrial dysfunction by preventing neuroin-
flammation. Supporting this idea, BV treatment signifi-
cantly increased the expression of a neuronal cell marker
and reduced GFAP levels when compared with age-
matched hSOD1
G93A transgenic mice (Figure 7A-B).
Accordingly, a reduced number of astrocytes and dimin-
ished cytokine levels positively influenced neuronal survi-
val and inhibited mitochondrial dysfunction which
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Page 6 of 12Figure 4 Immunoreactivity (IR) and western blotting for Iba1 in the brainstem and spinal cord. A representative blot of Iba-1 is shown
significant reduction of Iba I in the brainstem and spinal cord of BV-treated hSOD1
G93A mice (A). This experiment was performed using saline- or
BV-treated hSOD1
G93A mice (n = 3). Quantitative analysis of immunoblot. The image is representative of three independent experiments. The
optical density was measured for each band, and values for Iba-1 were compared with tubulin after correcting for the total protein content. The
Results of the densitometric quantifications are the means ± SEM of triplicate samples. The data were analyzed using a t-test. *p < 0.01 versus
the corresponding saline-treated group.
Iba1 IR of the lumbar (L4) spinal cord of hSOD1
G93A mice treated with saline (B) or BV (C). Boxes indicate high magnification views of the ventral
horn region. Iba1 IR of the facial nucleus of the brainstem from saline- (D) or BV-treated transgenic mice (E). Scale bars = 200 μm (B, C). Scale
bars = 100 μm (D, E). Cell counts of Iba1-positive cells in the ventral horn region or brainstem of saline- (black columns, n = 3) or BV-treated
mice (white columns, n = 4) (F, G). Data are shown as the mean ± SEM. Data were analyzed with a t-test. *p < 0.001. BV: bee venom, BS:
brainstem, SP: spinal cord.
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oxygen species (ROS) and glutamate release associated
with ALS [37]. With respect to the molecular mechanism
underlying BV, we observed that BV treatment triggered
a reduction in the activation of p38 MAPK, which is
downstream of the TNF-a signaling pathway in the
spinal cord of hSOD1mice (Figure 7D). In contrast, the
levels of phospho-AKT and phospho-ERK were increased
in both the brainstem and spinal cord of BV-treated
hSOD1 mice compared to those of control mice (Figure
7E-F). These results demonstrate that BV-treatment of
familial mutant hSOD1 transgenic mice caused a reduc-
tion in pro-inflammatory cytokines and an increase in
phospho-Akt and ERK, which may inhibit motor neuro-
nal cell death by preventing neuroninflammation and
consequently delay disease onset.
Figure 5 Immunohistochemical study of TNF-a in the brainstem and anterior horns of the lumbar (L4) spinal cord in BV- or saline-
treated familial mutant SOD1 mice. TNF-a IR is significantly reduced in the facial nucleus of the brainstem from BV-treated hSOD1
G93A mice
(A, B). Scale bars = 400 μm (A, B). High magnification of boxes (facial nucleus) in A and B (C, D). In the anterior horn of the spinal cord, the
number of TNF-a-immunoreactive cells was increased in hSOD1
G93A mice, but it was reduced by treatment with BV (E, F). Scale bars = 100 μm
(C-F). Cell counting for TNF-a immunoreactive cells in saline- (black columns, n = 3) or BV-treated (white columns, n = 4) hSOD1
G93A mice (G, H).
BV treatment reduced significantly TNF-a immunoreactivity in the brainstem (G) and lumbar spinal cord (H). Data were analyzed with a t-test. *p
< 0.001. AH: anterior horn.
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Page 8 of 12Figure 6 The effect of BV on mitochondrial dysfunction in symptomatic mutant hSOD1
G93A mice. A representative of Western blotting
analysis of the brainstem and lumbar spinal cord of BV- or saline-treated hSOD1
G93A mice (n = 3) using anti-active caspase-3 antibodies (A). The
image is representative of three independent experiments. The optical density was measured for each band, and values for Iba 1 were
compared with tubulin after correcting for the total protein content. The Results of the densitometric quantifications are the means ± SEM of
triplicate samples. The data were analyzed using a t-test. *p < 0.01 versus the corresponding saline-treated group. The expression level of active
caspase-3 protein in the lumbar spinal cord was dramatically reduced by treatment with BV in symptomatic hSOD1
G93A transgenic mice.
Transmission electron microscopy (TEM) of mitochondria in the lumbar spinal cord of saline- or BV-treated symptomatic hSOD1
G93A mice (B-E). In
symptomatic hSOD1
G93A mice, mitochondria displayed vacuolation (arrow, B) and broken cristae (arrow, D). However, BV treatment prohibited
collapse of the mitochondrial structure and loss of cristae in familial symptomatic hSOD1
G93A mice (C, E). BV: bee venom, BS: brainstem, SP:
spinal cord.
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Page 9 of 12Figure 7 BV treatment reduces the expression of GFAP protein and prevents neuronal cell death via modulation of cell survival
signaling pathways. A representative of Western blot analysis shows increased expression of the MAP protein (A), which is reduced in BV-
treated hSOD1
G93A mice at the symptomatic stage (B). The intensities of the immunoreactive bands were compared to the corresponding bands
from the brainstem or spinal cord of saline-treated mice (A). Quantification of the intensity of the immunoreactive band was compared to the
corresponding bands from the brainstem or spinal cord of BV-treated hSOD1
G93A mice (n = 3) (B). * indicates a non-specific immunoblot band.
Western blots show that the expression of active p38 in the spinal cord was reduced by BV treatment compared to the levels observed in age-
matched hSOD1
G93A mice (n = 3) (D). The expression level of phospho-Akt protein was increased in the brain stem and lumbar spinal cord by
BV treatment (E). The amount of phospho-ERK protein was augmented after BV treatment in tissue extracts from the brainstem and spinal cord
of hSDO1
G93A mice (F). Quantitative analysis of immunoblot. The image is representative of three independent experiments. The optical density
was measured for each band, and values for Iba-1 were compared with tubulin after correcting for the total protein content. The Results of the
densitometric quantifications are the means ± SEM of triplicate samples. The data were analyzed using a t-test. *p < 0.01 versus the
corresponding saline-treated group. BV: bee venom, BS: brainstem, SP: spinal cord.
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Page 10 of 12Conclusions
This study presented that the improved motor activity
and prolonged life span of BV-treated hSOD1
G93A mice
were attributable to the neuroprotective effect provide by
reduced levels of cytokines, which are typically released
by activated microglia and astrocytes. Furthermore, the
present study illustrated that BV treatment prevented
mitochondrial disruption and served a neuroprotective
role in vivo via the activation of cell survival signal trans-
duction pathways, such as the PI3K and ERK pathways,
which subsequently protected against the death of motor
neurons in symptomatic hSOD1
G93A mice.
Further challenges remaining will be to determine
whether bee venom treatment at other acupoints pre-
sents neuro-protective effects against neuroinflammation
in symptomatic ALS mice and find the potential bioactive
element of bee venom components in vivo and in vitro.
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